MRK's growing pipeline, acquired assets and new product launches are gaining traction as it builds a diversified growth base ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced ...

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...

Nevertheless, in the past year, Merck (MRK) delivered an impressive 73% return to investors, outpacing the S&P 500. The peak ...

Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so ...

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with ...

Moderna's personalized mRNA cancer therapy, developed with Merck, reduced the risk of melanoma recurrence and spread in a ...

Merck (MRK) stock slips as RBC Capital Markets cuts on valuation while Morgan Stanley upgrades on trial data for Moderna ...

A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...

Moderna and Merck have been running a large Phase III trial in over a thousand high-risk patients who had already had surgery ...

A late-stage trial that combined a messenger ribonucleic acid (mRNA) shot jointly developed by Moderna (MRNA +130.82%) and ...

Moderna's mRNA vaccine combined with Merck's immunotherapy Keytruda succeeded in a late-stage trial for skin cancer, the ...